Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

New Data Supports Dalazatide from Kv1.3 Therapeutics as a Potential Therapy for Inclusion Body Myositis (IBM)

biospaceApril 27, 2018

Tag: Kv1.3 Therapeutics , Myositis

PharmaSources Customer Service